Surface Oncology, Inc. (SURF): Price and Financial Metrics
GET POWR RATINGS... FREE!
SURF POWR Grades
- SURF scores best on the Value dimension, with a Value rank ahead of 98.71% of US stocks.
- The strongest trend for SURF is in Stability, which has been heading up over the past 199 days.
- SURF ranks lowest in Stability; there it ranks in the 7th percentile.
SURF Stock Summary
- SURF's went public 3.05 years ago, making it older than just 9.1% of listed US stocks we're tracking.
- In terms of twelve month growth in earnings before interest and taxes, Surface Oncology Inc is reporting a growth rate of -187.36%; that's higher than just 11.01% of US stocks.
- As for revenue growth, note that SURF's revenue has grown 125.71% over the past 12 months; that beats the revenue growth of 95.67% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Surface Oncology Inc, a group of peers worth examining would be GTHX, NPTN, DCPH, GTYH, and NXTC.
- Visit SURF's SEC page to see the company's official filings. To visit the company's web site, go to www.surfaceoncology.com.
SURF Stock Price Chart Interactive Chart >
SURF Price/Volume Stats
|Current price||$7.92||52-week high||$14.40|
|Prev. close||$7.51||52-week low||$2.39|
|Day high||$8.04||Avg. volume||1,486,036|
|50-day MA||$7.89||Dividend yield||N/A|
|200-day MA||$8.30||Market Cap||343.96M|
Surface Oncology, Inc. (SURF) Company Bio
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.
SURF Latest News Stream
|Loading, please wait...|
SURF Latest Social Stream
View Full SURF Social Stream
Latest SURF News From Around the Web
Below are the latest news stories about Surface Oncology Inc that investors may wish to consider to help them evaluate SURF as an investment opportunity.
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2021, as well as anticipated corporate milestones for the second quarter 2021. “The first quarter of 2021 marked a significant transition for Surface, and I am honored to become CEO during this very exciting time,” said Rob Ross, M.D., chief executive officer. “In June, we will be sharing data with the medical community and investors regarding the clinical progress we have made with our Phase 1 trials of both SRF617 and SRF388. We believe that both of these novel agents have the potential to improve outc...
SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on Friday, June 4th at 8:00 a.m. ET CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a scientific poster sharing clinical data from its Phase 1 study of SRF388 will be presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting, to be held virtually June 4-8, 2021. In conjunction, Surface will host a webcast on Friday, June 4, 2021 at 8:00 a.m. to review the SRF388 clinical data as well as to provid...
Henry Rath announced as chief business officer, Alison O’Neill as chief medical officer and Jessica Fees as chief financial officerCAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today the appointment of Henry Rath as chief business officer, and the promotions of Alison O’Neill, M.D. to chief medical officer and Jessica Fees to chief financial officer. Henry brings over twenty-five years of experience in the biotechnology industry, with roles spanning corporate finance, strategy, commercial planning, and business development. Prior to joining Surface, Henry worked at TScan Therapeutics, Seres Therapeutics, Amgen, Cata...
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal as one of the Best Places to Work in 2021. This exclusive distinction features Massachusetts companies that have built outstanding work environments. “This honor is a credit to every member of the Surface team. We strive to foster an environment with a strong sense of community and shared commitment to learning and working together to develop life-changing therapies for patients with cancer,” said Rob Ross, M.D., chief executive officer at Surface Oncology. “We are thrilled to be recognized as a Best Places to Work compan...
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting the company’s lead product programs, SRF388 (targeting IL-27) and SRF617 (targeting CD39). These data will be presented as part of the American Association for Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually April 10-15 and May 17-21, 2021. “These findings further support the biological rationale that both of our lead product candidates, SRF388 and SRF617, promote increased proinflammatory activity within the tumor microenvironment in the hopes of ultimately providing novel treatment options to patients with ca...
SURF Price Returns